Media
Better Outcomes Tracking: A First Step In Improving Access To New Treatments
Article featured in Health Affairs
MEDIA
Value creators or financial destroyers? The potential of gene therapies to transform healthcare
Article featured in STAT
New research brief: Emerging market solutions for financing and reimbursement of gene therapies for sickle cell disease: Why do payment innovation?
The FDA has approved two cell and gene therapies for sickle cell disease, marking a significant development for the largest population condition to date. However, the high treatment costs, budget impact, and unique challenges of SCD create a need for payment innovation to ensure access and sustainability for all stakeholders.
ICER / NEWDIGS White Paper: Managing the Challenges of Paying for Gene Therapy: Strategies for Market Action and Policy Reform
Shadowing the excitement about the transformational potential of many gene therapies has been widespread concern about the combination of uncertainty in the durability of their benefits over the long term and the short-term financial shock of high prices.
The white paper analyzes the intersecting challenges of ensuring patient access for gene therapies, including determining fair prices, managing clinical uncertainty, and mitigating financial shocks.